RYTM vs LLY vs NVO vs ABBV vs JNJ

For growth investors, Rhythm Pharmaceuticals, Inc.

(RYTM) is the stronger pick with 45. 8% revenue growth year-over-year, versus 4. 3% for Johnson & Johnson (JNJ). Novo Nordisk A/S (NVO) offers the better valuation at 12. 7x trailing P/E (2. 1x forward), making it the more compelling value choice. Analysts rate Rhythm Pharmaceuticals, Inc. (RYTM) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Novo Nordisk A/S (NVO) is the cheapest at 12.

7x versus AbbVie Inc. at 85. 0x. On forward P/E, Novo Nordisk A/S is actually cheaper at 2. 1x. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: Novo Nordisk A/S wins at 0. 10x versus Johnson & Johnson's 34. 02x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, Eli Lilly and Company (LLY) delivered a total return of +399.

3%, compared to +35. 9% for Novo Nordisk A/S (NVO). Over 10 years, the gap is even starker: LLY returned +1203% versus NVO's +100. 4%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Johnson & Johnson (JNJ) is the lower-risk stock at 0.

04β versus Novo Nordisk A/S's 1. 52β — meaning NVO is approximately 3292% more volatile than JNJ relative to the S&P 500. On balance sheet safety, Johnson & Johnson (JNJ) carries a lower debt/equity ratio of 51% versus 177% for Rhythm Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Rhythm Pharmaceuticals, Inc.

(RYTM) is pulling ahead at 45. 8% versus 4. 3% for Johnson & Johnson (JNJ). On earnings-per-share growth, the picture is similar: Eli Lilly and Company grew EPS 96. 0% year-over-year, compared to -57. 8% for Johnson & Johnson. Over a 3-year CAGR, RYTM leads at 100. 2% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Novo Nordisk A/S (NVO) is the more profitable company, earning 33.

1% net margin versus -103. 6% for Rhythm Pharmaceuticals, Inc. — meaning it keeps 33. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: LLY leads at 45. 6% versus -101. 2% for RYTM. At the gross margin level — before operating expenses — RYTM leads at 89. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, Novo Nordisk A/S (NVO) is the more undervalued stock at a PEG of 0. 10x versus Johnson & Johnson's 34. 02x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Novo Nordisk A/S (NVO) trades at 2. 1x forward P/E versus 26. 3x for Eli Lilly and Company — 24. 2x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for RYTM: 48. 9% to $140. 20.

In this comparison, NVO (4.

0% yield), ABBV (3. 3% yield), JNJ (2. 2% yield), LLY (0. 6% yield) pay a dividend. RYTM does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Eli Lilly and Company (LLY) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.

65), 0. 6% yield, +1203% 10Y return). Both have compounded well over 10 years (LLY: +1203%, RYTM: +213. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: RYTM is a small-cap high-growth stock; LLY is a large-cap high-growth stock; NVO is a large-cap deep-value stock; ABBV is a large-cap income-oriented stock; JNJ is a large-cap quality compounder stock. LLY, NVO, ABBV, JNJ pay a dividend while RYTM does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.